Es gibt bei Ärzten noch große Verwirrung bezüglich #Paxlovid, der Tablettentherapie für Risikopatienten mit Coronainfektion.Bitte bei richtigen Indikation mutig verordnen! Man muss nur Medikamenten Wechselwirkungen beachten und umbasteln!Ein Thread: 1/x#impfluencer pic.twitter.com/zNoc8wutCm— Dr. Christian Kroener 📯 (@Chrissip81) March 17, 2022
‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
The COVID-19 pandemic caused much illness, many deaths, and profound disruption to society. The production of ‘safe and effective’ vaccines was a key public health target. Sadly, unprecedented high rates of adverse events have overshadowed the benefits. This two-part narrative review presents evidence for the widespread harms of novel product COVID-19 mRNA and adenovectorDNA vaccines and is novel in attempting to provide a thorough overview of harms arising from the new technology in vaccines that relied on human cells producing a foreign antigen that has evidence of pathogenicity. This first paper explores peer-reviewed data counter to the ‘safe and effective’ narrative attached to these new technologies. Spike protein pathogenicity, termed ‘spikeopathy’, whether from the SARS-CoV-2 virus or produced by vaccine gene codes, akin to a ‘synthetic virus’, is increasingly understood in terms of molecular biology and pathophysiology. Pharmacokinetic transfection through body tissues distant from the injection site by lipid-nanoparticles or viral-vector carriers means that ‘spikeopathy’ can affect many organs. The inflammatory properties of the nanoparticles used to ferry mRNA; N1-methylpseudouridine employed to prolong synthetic mRNA function; the widespread biodistribution of the mRNA and DNA codes and translated spike proteins, and autoimmunity via human production of foreign proteins, contribute to harmful effects. This paper reviews autoimmune, cardiovascular, neurological, potential oncological effects, and autopsy evidence for spikeopathy. With many gene-based therapeutic technologies planned, a re-evaluation is necessary and timely.
IgG3 subclass antibodies recognize antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent binding | Proceedings of the National Academy of Sciences
The constant domains of antibodies are important for effector functions, but less is known about how they can affect binding and neutralization of ...
Neue PASC-Falldefinition: Jeder zehnte Patient leidet nach Omikron-Infektion unter Long COVID
Boston – Das milliardenschwere RECOVER-Projekt der US-National Institutes of Health hat eine Falldefinition für die postakuten Folgen einer SARS-CoV-2-Infektion...
Nature Medicine - Analysis of data from the US Department of Veterans Affairs showed that 2 years after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, risk for most...
Fig. 1: Risk of postacute sequelae of COVID-19 up to 2 years after infection by care setting of the acute phase of the disease.Relative risks by days after infection plotted for time periods of 30–90, 91–180, 181–360, 361–540 and 541–720 days after infection, labeled by the last day of the corresponding time period. Heatmaps include (top row) nonhospitalized for COVID-19 during the acute phase of the disease (n = 118,238) corresponding to each sequela and (bottom row) COVID-19 hospitalization during the acute phase of the disease (n = 20,580). Relative risks were estimated in comparison to a noninfected control (n = 5,985,227). Sequelae are grouped by organ system. ACD, acute coronary disease; AIM, abnormal involuntary movements; AKI, acute kidney injury; CKD, chronic kidney disease; DVT, deep vein thrombosis; ESKD, end-stage kidney disease; GAD, general anxiety disorder; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome; ICM, ischemic cardiomyopathy; ILD, interstitial lung disease; MI, myocardial infarction; NCD, neurocognitive decline; NICM, nonischemic cardiomyopathy; PTSD, post-traumatic stress disorder; PUD, peptic ulcer disease; TIA, transient ischemic attack; VTE, venous thromboembolism. NS, non-significant.
Nature Medicine - Analysis of data from the US Department of Veterans Affairs showed that 2 years after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, risk for most...
Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities
Counterintuitively, SARS-CoV-2 Omicron infection was associated with increased risk
of Omicron reinfection in residents of long-term care and retirement homes. Less robust
humoral hybrid immune responses in older adults may contribute to risk of Omicron
reinfection.
Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort
Post-COVID-19 syndrome (PCS) is characterised by a wide range of symptoms, primarily fatigue and exertion intolerance. While disease courses in the ea…
Seroepidemiology of the Seasonal Human Coronaviruses NL63, 229E, OC43 and HKU1 in France
AbstractBackground. The seasonal human coronaviruses (HCoV) NL63, 229E, OC43, and HKU1 are globally endemic, yet the majority of HCoV infections remain undiagno
Seroepidemiology of Seasonal Human Coronaviruses NL63, 229E, OC43, HKU1 in France; rate of waning of anti-HCoV spike IgG Ab, estimated as 0.22–0.47 year−1 for children, 0.13–0.27 year−1 for adults. https://t.co/W0EH1zjO7j— Prof. Dr. Sanjeev Bagai (@BagaiDr) August 22, 2023
Incidence of New-Onset Hypertension Post–COVID-19: Comparison With Influenza
BACKGROUND: SARS-CoV-2 may trigger new-onset persistent hypertension. This study investigated the incidence and risk factors associated with new-onset persistent hypertension during COVID-19 hospital
Two new papers @NatureMedicine and @JAMAInternalMed shed light on #LongCovid at 2-years. But there's no shortage of known unknowns.Reviewed in a new Ground Truths (link in my profile, because that would be it X-suppressed) pic.twitter.com/5CePVxePQa— Eric Topol (@EricTopol) August 21, 2023
The bigger surprise, the new BA.2.86 sample(USA, traveler from Japan) has no genomic connection to neither the Danish nor the Israeli branch. This makes the picture only more complicated as there must already be an ongoing worldwide spread! Trashed testing and surveillance… pic.twitter.com/B5pMLWymzZ— Harry Spoelstra (@HarrySpoelstra) August 22, 2023
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus - PubMed
These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SA …
Einstellung der adjustierten Hospitalisierungen · Issue #35 · robert-koch-institut/COVID-19-Hospitalisierungen_in_Deutschland
Liebe User, durch die aktuell im Vergleich geringeren Hospitalisierungszahlen ist eine Adjustierung dieser Zahlen nicht verlässlich möglich. Deshalb wird die Adjustierung der Hospitalisierungen bis...
Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron
Communications Biology - Analysis of next-generation sequencing data linked with clinical metadata from individuals reinfected with SARS-CoV-2 in a Danish cohort reveals that Omicron reinfections...
Wastewater-based epidemiology predicts COVID-19-induced weekly new hospital admissions in over 150 USA counties
Nature Communications - Wastewater-based epidemiology is increasingly used to predict disease occurrence. Here, the authors use SARS-CoV-2 RNA concentrations in wastewater in machine learning...
A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation
The coronavirus disease 2019 (COVID-19) pandemic underscores the need to better understand animal-to-human transmission of coronaviruses and adaptive evolution within new hosts. We scanned more than 182,000 severe acute respiratory syndrome coronavirus ...
COVID-19 Impairs Immune Response to Candida albicans
Infection with SARS-CoV-2 can lead to Coronavirus disease-2019 (COVID-19) and result in severe acute respiratory distress syndrome (ARDS). Recent reports indicate an increased rate of fungal coinfections during COVID-19. With incomplete understanding of the pathogenesis and without any causative therapy available, secondary infections may be detrimental to the prognosis. We monitored 11 COVID-19 patients with ARDS for their immune phenotype, plasma cytokines, and clinical parameters on the day of ICU admission and on day 4 and day 7 of their ICU stay. Whole blood stimulation assays with lipopolysaccharide (LPS), heat-killed Listeria monocytogenes (HKLM), Aspergillus fumigatus, and Candida albicans were used to mimic secondary infections, and changes in immune phenotype and cytokine release were assessed. COVID-19 patients displayed an immune phenotype characterized by increased HLA-DR+CD38+ and PD-1+ CD4+ and CD8+ T cells, and elevated CD8+CD244+ lymphocytes, compared to healthy controls. Monocyte activation markers and cytokines IL-6, IL-8, TNF, IL-10, and sIL2Rα were elevated, corresponding to monocyte activation syndrome, while IL-1β levels were low. LPS, HKLM and Aspergillus fumigatus antigen stimulation provoked an immune response that did not differ between COVID-19 patients and healthy controls, while COVID-19 patients showed an attenuated monocyte CD80 upregulation and abrogated release of IL-6, TNF, IL-1α, and IL-1β toward Candida albicans. This study adds further...
Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients
Cellular & Molecular Immunology - Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients
Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients - PubMed
A low count of CD4+ and CD8+ lymphocytes is a hallmark laboratory finding in the coronavirus disease 2019 (COVID-19). Using flow cytometry, we observed significantly higher CD95 (Fas) and PD-1 expression on both CD4+ T and CD8+ T cells in 42 COVID-19 patie …
SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent of a major global outbreak of respiratory tract disease known as coronavirus disease-2019 (COVID-19). SARS-CoV-2 infects the lungs and may cause several immune-related complications such as lymphocytopenia and cytokine storm which are associated with the severity of the disease and predict mortality[1][1],[2][2]. The mechanism by which SARS-CoV-2 infection may result in immune system dysfunction is not fully understood. Here we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients. We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS-CoV-2 in T helper cells in a mechanism that also requires ACE2 and TMPRSS2. Once inside T helper cells, SARS-CoV-2 assembles viral factories, impairs cell function and may cause cell death. SARS-CoV-2 infected T helper cells express higher amounts of IL-10, which is associated with viral persistence and disease severity. Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may explain the poor adaptive immune response of many COVID-19 patients. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by grants from FAEPEX-UNICAMP (#2295/20, #2458/20, #2266/20 and #2274/20), Sao Paulo Research Foundation (FAPESP) (#2019/16116-4, #2019/06372-3, #2020/04583-4, #2013/08293-7, #2020/04579-7, #2015/15626-8, #2018/14933-2, #2020/04746-0, #2019/00098-7, #2020/04919-2, #2017/01184-9), the National Institute of Science and Technology in Neuroimmunomodulation (INCT-NIM) (#465489/2014-1) and FINEP (#01.20.0003.00). A.S.F. and M.A.M. were supported by CNPq productivity awards (#306248/2017-4 and #310287/2018-9). A.J.R.F, G.G.D., A.C.C., N.S.B., L.B.M., F.C., V.C.C., A.B., T.L.K, G.S.P., R.G.L. were supported by FAPESP fellowships (#2019/17007-4, #2019/22398-2, #2019/05155-9, #2019/06459-1, #2019/04726-2, #2017/23920-9, #2016/24163-4, #2016/23328-0). V.O.B. and L.N.S. were supported by FAEPEX fellowship (#2295/20 and #2319/20). D.M. was supported by CAPES fellowship. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The present study was approved by the University of Campinas Committee for Ethical Research (CAAE number 32078620.4.0000.5404). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are storage in the university databank and will be provided under reasonable request. [1]: #ref-1 [2]: #ref-2
Broad phenotypic alterations and potential dysfunctions of lymphocytes in COVID-19 recovered individuals
Background Lymphopenia is a typical symptom in the COVID-19 patients. While millions of patients are clinical recovered, little is known about the immune status of lymphocytes in these individuals. Methods A clinical recovered cohort (CR) of 55 COVID-19 individuals (discharged from hospital 4 to 11 weeks), and 55 age and sex matched healthy donors cohort (HD) were recruited. Detailed analysis on phenotype of the lymphocytes in peripheral blood mononuclear cells (PBMCs) was performed by flow cytometry. Findings Compared with cohort HD, the CD8+ T cells in cohort CR had higher Teff and Tem, but lower Tc1 (IFN-γ+), Tc2 (IL-4+) and Tc17 (IL-17A+) frequencies. The CD4+ T cells of CR had decreased frequency, especially on the Tcm subset. Moreover, CD4+ T cells of CR expressed lower PD-1 and had lower frequencies of Th1 (IFN-γ+), Th2 (IL-4+), Th17 (IL-17A+) as well as circulating Tfh (CXCR5+PD-1+). Accordingly, isotype-switched memory B cell (IgM-CD20hi) in CR had significantly lower proportion in B cells, though level of activation marker CD71 elevated. For CD3-HLA-DRlo lymphocytes of CR, besides levels of IFN-γ, Granzyme B and T-bet were lower, the correlation between T-bet and IFN-γ became irrelevant. In addition, taken into account of discharged days, all the lowered function associated phenotypes showed no recovery tendency within whole observation period. Interpretation The CR COVID-19 individuals still showed remarkable phenotypic alterations in lymphocytes after clinical recovery 4 to 11 weeks. This suggests SARS-CoV-2 infection imprints profoundly on lymphocytes and results in long-lasting potential dysfunctions. Funding Kunming Science and Technology Department (2020-1-N-037) ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement Funding Kunming Science and Technology Department (2020-1-N-037) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was reviewed and approved by the Medical Ethical Committee of Wuhan Jinyintan hospital (approval number KY-2020-47.01). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes I can provide the data of this study if required.
Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients
Given the known immuno- and neuro-pathogenicity of HERV-W ENV protein, it could promote certain pathogenic features of COVID-19 and therefore serve as a biomarker to predict clinical progression of disease and open to further studies for therapeutic intervention.
Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread widely. The aim…
